Terms: = Endocrine gland cancer AND NFATC2, ENSG00000101096, 4773, Q13469, NFATP, NFAT1, KIAA0611
19 results:
1. Effect of nfatc2- and Sp1-mediated TNFalpha Regulation on the Proliferation and Migration Behavior of Pancreatic cancer Cells.
Malsy M; Graf B; Bruendl E; Maier-Stocker C; Bundscherer A
Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):706-711. PubMed ID: 38035702
[TBL] [Abstract] [Full Text] [Related]
2. Over-expression of cFos by the Transcription Factors nfatc2 and Sp1 in Pancreatic cancer Cells.
Malsy M; Graf B; Bruendl E; Maier-Stocker C; Bundscherer A
Anticancer Res; 2023 Nov; 43(11):4897-4904. PubMed ID: 37909980
[TBL] [Abstract] [Full Text] [Related]
3. A Data-Driven Approach to Refine Predictions of Differentiated Thyroid cancer Outcomes: A Prospective Multicenter Study.
Grani G; Gentili M; Siciliano F; Albano D; Zilioli V; Morelli S; Puxeddu E; Zatelli MC; Gagliardi I; Piovesan A; Nervo A; Crocetti U; Massa M; Samà MT; Mele C; Deandrea M; Fugazzola L; Puligheddu B; Antonelli A; Rossetto R; D'Amore A; Ceresini G; Castello R; Solaroli E; Centanni M; Monti S; Magri F; Bruno R; Sparano C; Pezzullo L; Crescenzi A; Mian C; Tumino D; Repaci A; Castagna MG; Triggiani V; Porcelli T; Meringolo D; Locati L; Spiazzi G; Di Dalmazi G; Anagnostopoulos A; Leonardi S; Filetti S; Durante C
J Clin Endocrinol Metab; 2023 Jul; 108(8):1921-1928. PubMed ID: 36795619
[TBL] [Abstract] [Full Text] [Related]
4. Role of DNA Repair Variants and Diagnostic Radiology Exams in Differentiated Thyroid cancer Risk: A Pooled Analysis of Two Case-Control Studies.
Zidane M; Truong T; Lesueur F; Xhaard C; Cordina-Duverger E; Boland A; Blanché H; Ory C; Chevillard S; Deleuze JF; Souchard V; Ren Y; Zemmache MZ; Canale S; Borson-Chazot F; Schvartz C; Mariné Barjoan E; Guizard AV; Laurent-Puig P; Mulot C; Guibon J; Karimi M; Schlumberger M; Adjadj E; Rubino C; Guenel P; Cazier JB; de Vathaire F
Cancer Epidemiol Biomarkers Prev; 2021 Jun; 30(6):1208-1217. PubMed ID: 33827984
[TBL] [Abstract] [Full Text] [Related]
5. A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
Cadoo KA; Grisham RN; O'Cearbhaill RE; Boucicaut NN; Henson M; Iasonos A; Zhou Q; Sarasohn DM; Gallagher J; Kravetz S; Zamarin D; Makker V; Sabbatini PJ; Tew WP; Aghajanian C; Konner JA
Gynecol Oncol; 2020 Apr; 157(1):214-221. PubMed ID: 31959492
[TBL] [Abstract] [Full Text] [Related]
6. The Effects of Analgesics and Local Anesthetics on Gene Transcription Mediated by nfatc2 and Sp1 in Pancreatic Carcinoma.
Malsy M; Graf B; Bundscherer A
Anticancer Res; 2019 Sep; 39(9):4721-4728. PubMed ID: 31519571
[TBL] [Abstract] [Full Text] [Related]
7. Down-regulated
Zeng J; Ma X; Wang J; Liu R; Shao Y; Hou Y; Li Z; Fang Y
Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31101684
[TBL] [Abstract] [Full Text] [Related]
8. The active role of the transcription factor Sp1 in nfatc2-mediated gene regulation in pancreatic cancer.
Malsy M; Graf B; Almstedt K
BMC Biochem; 2019 Jan; 20(1):2. PubMed ID: 30696421
[TBL] [Abstract] [Full Text] [Related]
9. Identifying risk factors for recurrence of papillary thyroid cancer in patients who underwent modified radical neck dissection.
Ryu YJ; Cho JS; Yoon JH; Park MH
World J Surg Oncol; 2018 Oct; 16(1):205. PubMed ID: 30314503
[TBL] [Abstract] [Full Text] [Related]
10. [Optimal cytoreduction in advanced ovarian cancer treated with dose-dense paclitaxel and carboplatin followed by interval surgery at the Peruvian National Institute of Neoplastic Diseases].
Alcarraz C; Muñiz J; Mas L; Olivera M; Morante Z; Alvarez M; Mantilla R; Araujo J; Pinto J
Rev Peru Med Exp Salud Publica; 2018; 35(1):46-54. PubMed ID: 29924276
[TBL] [Abstract] [Full Text] [Related]
11. Compensation Claims for Sub-substandard Care of Patients with Gastroentero-pancreatic Neuroendocrine Tumors: A Nationwide Descriptive Study of Cases Between 2005-2016 in Norway.
Desserud KF; Bukholm I; Søreide JA
Anticancer Res; 2017 Oct; 37(10):5667-5671. PubMed ID: 28982884
[TBL] [Abstract] [Full Text] [Related]
12. Interaction between nfatc2 and the transcription factor Sp1 in pancreatic carcinoma cells PaTu 8988t.
Malsy M; Graf B; Almstedt K
BMC Mol Biol; 2017 Aug; 18(1):20. PubMed ID: 28774282
[TBL] [Abstract] [Full Text] [Related]
13. Huwe1 Sustains Normal Ovarian Epithelial Cell Transformation and Tumor Growth through the Histone H1.3-
Yang D; Sun B; Zhang X; Cheng D; Yu X; Yan L; Li L; An S; Jiang H; Lasorella A; Iavarone A; Zhang S; Zou F; Zhao X
Cancer Res; 2017 Sep; 77(18):4773-4784. PubMed ID: 28687618
[TBL] [Abstract] [Full Text] [Related]
14. Randomized trial comparing a side-port needle and standard needle for EUS-guided histology of pancreatic lesions.
Ishiwatari H; Hayashi T; Kawakami H; Isayama H; Hisai H; Itoi T; Ono M; Kawakubo K; Yamamoto N; Tanaka M; Itokawa F; Oshiro H; Sonoda T; Hasegawa T;
Gastrointest Endosc; 2016 Oct; 84(4):670-8. PubMed ID: 26995688
[TBL] [Abstract] [Full Text] [Related]
15. GSK-3β Governs Inflammation-Induced nfatc2 Signaling Hubs to Promote Pancreatic cancer Progression.
Baumgart S; Chen NM; Zhang JS; Billadeau DD; Gaisina IN; Kozikowski AP; Singh SK; Fink D; Ströbel P; Klindt C; Zhang L; Bamlet WR; Koenig A; Hessmann E; Gress TM; Ellenrieder V; Neesse A
Mol Cancer Ther; 2016 Mar; 15(3):491-502. PubMed ID: 26823495
[TBL] [Abstract] [Full Text] [Related]
16. c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells.
Geismann C; Grohmann F; Sebens S; Wirths G; Dreher A; Häsler R; Rosenstiel P; Hauser C; Egberts JH; Trauzold A; Schneider G; Sipos B; Zeissig S; Schreiber S; Schäfer H; Arlt A
Cell Death Dis; 2014 Oct; 5(10):e1455. PubMed ID: 25299780
[TBL] [Abstract] [Full Text] [Related]
17. WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer.
Griesmann H; Ripka S; Pralle M; Ellenrieder V; Baumgart S; Buchholz M; Pilarsky C; Aust D; Gress TM; Michl P
Neoplasia; 2013 Jan; 15(1):11-22. PubMed ID: 23359789
[TBL] [Abstract] [Full Text] [Related]
18. Restricted heterochromatin formation links nfatc2 repressor activity with growth promotion in pancreatic cancer.
Baumgart S; Glesel E; Singh G; Chen NM; Reutlinger K; Zhang J; Billadeau DD; Fernandez-Zapico ME; Gress TM; Singh SK; Ellenrieder V
Gastroenterology; 2012 Feb; 142(2):388-98.e1-7. PubMed ID: 22079596
[TBL] [Abstract] [Full Text] [Related]
19. Disruption of a nuclear nfatc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid.
Singh SK; Baumgart S; Singh G; König AO; Reutlinger K; Hofbauer LC; Barth P; Gress TM; Lomberk G; Urrutia R; Fernandez-Zapico ME; Ellenrieder V
J Biol Chem; 2011 Aug; 286(33):28761-28771. PubMed ID: 21628454
[TBL] [Abstract] [Full Text] [Related]
